A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Inclusion Criteria:

1. Confirmed Multiple Sclerosis (MS) diagnosis.

2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior tostudy start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) buthave not yet received their first infusion on Day 1 of 150 milligrams (mg) can beincluded.

Exclusion Criteria:

1. Have received any live or live-attenuated vaccines (including for varicella-zostervirus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy)administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.

2. Any active infection (e.g., active Hepatitis B virus [HBV])

3. Concurrent participation in any interventional MS trials, or planned concurrenttreatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) duringthe study period.